Incorporation of bevacizumab in the primary treatment of ovarian cancer. - Wikidata - awgldk - TriplyDB

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

http://www.wikidata.org/entity/Q44579933

about

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer Management of relapsed ovarian cancer: a review Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Clinical relevance of circulating cell-free microRNAs in ovarian cancer Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment Chemotherapy of ovarian cancer in elderly patients Personalized medicine in gastric cancer: Where are we and where are we going?Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Role of mesenchymal cells in the natural history of ovarian cancer: a review Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Targeted anti-vascular therapies for ovarian cancer: current evidence Critical appraisal of bevacizumab in the treatment of ovarian cancer Lessons learned from the bevacizumab experience Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials Ovarian cancer standard of care: are there real alternatives?Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Practical management of bevacizumab-related toxicities in glioblastoma Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Contemporary use of bevacizumab in ovarian cancer Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma Current status and evolution of preclinical drug development models of epithelial ovarian cancer Patient preferences in advanced or recurrent ovarian cancer.Advanced ovarian cancer: what should be the standard of care?Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Antiangiogenic therapies in ovarian cancer The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review Bevacizumab in ovarian cancer: A critical review of phase III studies Major clinical research advances in gynecologic cancer in 2015 Precision targeted therapy of ovarian cancer

P2860

Q24202975-061EF0AE-8DA5-4CD3-B741-4B6691299EE7 Q26741755-67940B4A-0403-4B58-95CB-4CA2E80E39B2 Q26746067-EAB8468C-C3CA-4D6E-8F4C-54BA6ABF5F85 Q26747154-B7F10386-9691-4BD3-8B9C-6AFEE2A359BD Q26750649-F7160B7A-FAC3-4459-837F-1E784A9E816B Q26751280-668E33E8-DADD-4EA3-814A-2BD7168BB305 Q26769963-22264A4C-EC11-4300-A9AE-1997D089ECE5 Q26771397-6DE3A742-7249-44B3-9A91-BDB79779C83B Q26774521-5C9E9449-92AC-4928-B8D1-A548434AB919 Q26777453-AA54A026-D508-4FF2-B059-D57C2F0FAFBD Q26777846-8AE3DEFD-5A43-4BD0-B844-B6487F99EC1A Q26779120-C9F6AD5A-3689-4B21-96EC-064A29487C21 Q26780387-CEF25C37-3A32-4AFB-BA7C-24DDF3666AAD Q26781561-D18B34F3-FC05-4842-8C51-1AB17EABEA17 Q26786618-D969D58C-FADE-4921-931A-F18038F01E74 Q26823555-D9C49A7F-60E5-441E-9307-F51F53B04A34 Q26826899-6E147339-BEEC-4078-B9C0-50280F78294D Q26830287-42A14ADF-C00A-4FB5-9D19-F3C2A06D6B68 Q26830403-1E4B45C4-F1E5-4359-B803-C5D3A8576BE9 Q26852509-6E0ACAB0-522D-402E-85BF-18E1B135B343 Q26858830-457E2597-3982-4DF4-98EE-E5FE798E0638 Q26862249-00BE35A8-1197-49E9-BB4E-9678D46DE8CF Q26991997-78BA0DEE-441B-4367-A4F0-845D7974AA28 Q27001560-FD170F3B-BB9A-4147-829C-F18740324A79 Q27011282-567BE24C-2C0B-4B54-866B-F74CFEAB20FB Q27011840-78C6A4CE-43FE-41C9-8BEA-99707141FDBD Q27015852-773A5BA2-46C0-40BA-8F1C-06C39FF62C75 Q27016629-8676B4F8-BE39-41BD-883E-4BFE7BB6ADD4 Q27023510-89810FE5-05EB-4838-A584-9F2405419812 Q27024235-579CD5EB-1AA1-4C9E-AB47-8277C5DE635A Q27024948-3B0BCED5-3858-4DA8-962C-A486AC365618 Q27028117-BD2AB902-BE44-42FF-9FA6-E7C8BAA3D209 Q27336251-7901C03D-F14D-4AC6-BE35-383A360C7A7F Q27852053-56F832A5-1D86-418C-8CC8-7CB2B0F05E88 Q28073057-674CF2FA-7F2F-4835-B63F-25685FCD839A Q28073722-BC95D62F-024E-4A7C-AA06-5F1161CC547F Q28074666-8B0CB819-F63C-48F2-A8AE-08A4A5BB634A Q28076188-63376AC7-B036-49C8-945C-3695A8AFFF3A Q28077183-65C64699-6F17-4337-8B4F-8B76DA89A8BC Q28078658-ABBA1F31-6181-4024-AC4B-075BB75B0DC4

P2860

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

http://www.wikidata.org/entity/Q44579933

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@en

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@nl

type

label

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@en

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@nl

prefLabel

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@en

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@nl

P1433

Q44579933-9D9514BC-8F00-44F2-A975-50DB22D6F8FC

P1476

Q44579933-E95F5DA7-80D1-43E4-9FA6-0EF06D780143

P2093

Q44579933-06502054-C68A-42D8-A61D-2AF750C19A22

Q44579933-1DAD5DE2-03A0-49D6-A85E-F2908BDFD3A0

Q44579933-228B41A8-1DBD-4CD9-BA3E-575825ED2912

Q44579933-2350938A-50DA-456C-B42A-31EA8A6FECBD

Q44579933-3E3D3C97-1130-4E60-821A-E7A68A3E7407

Q44579933-4B2ADD47-C5E6-4C75-BD32-01F6DB7A30AE

Q44579933-564D6C05-CF09-4E4B-B69F-BAEAA413F4CE

Q44579933-5B4ABB1C-202E-4E9F-AF6F-5ACB8458C891

Q44579933-662E5821-963A-485B-9CCF-E9DBCEF6E296

Q44579933-99650C04-F755-4841-80DB-9E02DF6C9FE1

P304

Q44579933-95695AA9-62DC-40E6-BC54-030C5F37AB6B

P31

Q44579933-E8ADAE9D-0BED-41F1-973F-C4FBF7DD92EB

P356

Q44579933-63FCE2CB-6B94-4FA7-BE06-E05CA279AC72

P407

Q44579933-6A71A13E-03D4-4C1F-B170-68F3D8F4EEEF

P433

Q44579933-9144125D-7CE2-4CC1-91BC-1AD97F506C70

P478

Q44579933-321BF671-6802-41E9-926C-5E00727D83AE

P577

Q44579933-A28B82AB-87BE-4A22-9FD9-1E8820A6BE72

P698

Q44579933-7855CBEC-B696-4001-A63A-FE7D752E403E

P921

Q44579933-8F5A7026-2420-4F60-B964-2F04DF01690C

Q44579933-D246FDFF-08A4-4164-B376-D8A6D72EA121

P356

P1433

The New England Journal of Medicine

P1476

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

@en

P2093

Benjamin E Greer

http://www.w3.org/2001/XMLSchema#string

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Gini F Fleming

http://www.w3.org/2001/XMLSchema#string

Gynecologic Oncology Group

http://www.w3.org/2001/XMLSchema#string

Helen Huang

http://www.w3.org/2001/XMLSchema#string

Howard D Homesley

http://www.w3.org/2001/XMLSchema#string

Jeffrey Fowler

http://www.w3.org/2001/XMLSchema#string

Mark F Brady

http://www.w3.org/2001/XMLSchema#string

Matthew Boente

http://www.w3.org/2001/XMLSchema#string

Michael A Bookman

http://www.w3.org/2001/XMLSchema#string

P304

2473-2483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1104390

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22204724

http://www.w3.org/2001/XMLSchema#string

P921